Efficacy and Safety of Low-Dose Tolvaptan (7.5 mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study
In our view, tolvaptan can be initiated with a 7.5 mg dose, accompanied by Na + monitoring at 12 and 24 hours. If a second dose is necessary, 7.5 mg is comparably effective to a 15 mg dose, depending on the initial response. Further monitoring should include Na + concentration at around 24 hours after the second dose.
Authors
- Georgios K. Dimitriadis (ORCID: https://orcid.org/0000-0002-6662-804X)
- Royce P Vincent (ORCID: https://orcid.org/0000-0003-0743-4189)
- David R. Taylor (ORCID: https://orcid.org/0000-0003-1385-3961)
- Simon Aylwin (ORCID: https://orcid.org/0000-0001-9411-9456)
- David C. Llewellyn (ORCID: https://orcid.org/0009-0007-9453-0975)
- Corrine Byrne
- Eduard Oštarijaš (ORCID: https://orcid.org/0000-0001-9999-9886)
- S. Sahadevan (ORCID: https://orcid.org/0009-0003-0493-277X)
- Thitikorn Nuamek
Institutions
- Princess Royal University Hospital (GB)
- King's College Hospital NHS Foundation Trust (GB)
- The Christie NHS Foundation Trust (GB)
- University of Osijek (HR)
Publication Details
- Journal
- Endocrine Practice
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.eprac.2024.12.019
- Citations
- 3
- Primary Topic
- Electrolyte and hormonal disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.26